RxDoctor Payments Data

Lorraine Cho Chung Hing, MD

Nephrology · Venice, FLNPI 1285626499

Payments from drug & device makers

$2,600in general payments, 2019–2025

Across 133 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$510
  • Amgen$410
  • Akebia Therapeutics Inc$307
  • Fresenius USA Marketing, Inc.$252
  • Otsuka America Pharmaceutical, Inc.$196
  • OPKO Pharmaceuticals, LLC$195
  • plus $730 from 10 others

What the payments were for

  • Food & beverage$2,49596%
  • Education$1064%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,600 in reported general payments places this provider in the 55th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$462,371
Medicare patients
993
Services billed
4,877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin100$129,232
FarxigaDapagliflozin Propanediol49$74,345
ThiolaTiopronin13$64,950
VelphoroSucroferric Oxyhydroxide12$40,863
VeltassaPatiromer Calcium Sorbitex36$27,443
LokelmaSodium Zirconium Cyclosilicate41$27,355
Bumetanide103$6,838
Sevelamer Carbonate23$3,641
Potassium Citrate ErPotassium Citrate20$3,378
Potassium Chloride50$3,001
Allopurinol264$2,501
Olmesartan Medoxomil72$1,769
Doxazosin Mesylate73$1,410
Nifedipine ErNifedipine31$1,396
Hydralazine Hcl26$990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$48$129,232100 claims
AstraZenecaFarxiga, Lokelma$510$101,70090 claims
Fresenius USA Marketing, Inc.Velphoro$252$40,86312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 756 nephrology providers in Florida.

Other nephrology in Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →